Search results
Results From The WOW.Com Content Network
There was good news to share, but the market focused on a declining sales forecast and hammered the stock lower. Last November, Moderna said it expected 2024 revenue to land in a range between $3 ...
Moderna stock gained 14%, shooting up to $48.56 per share Tuesday afternoon. Vaccine-makers Novavax and CureVac similarly rose, soaring 15% and 10%, respectively, while Pfizer gained 2% and GSK ...
Does all this make Moderna a bad-news buy for 2025? This depends on your comfort with risk. Moderna may reach its product approval and launch goals -- but this will take a few years.
But Moderna's news hasn't been as bright recently. Last month, the company revised coronavirus vaccine revenue downward due to lower sales. And in its update this week, the biotech made ...
Year to date, Moderna stock has plunged over 60%, with a 52-week low-high of $35.8-$170.47, as per data from Benzinga Pro. ... Moderna unveiled key updates at its annual R&D Day in September ...
Moderna's (NASDAQ: MRNA) wild success in the COVID-19 vaccine market has worn off. Despite what it seems, though, Moderna has made clinical and regulatory progress. Let's find out whether this ...
The company's stock was trading slightly up on the news early Monday before falling after market open. Moderna is up almost 20% in the last month after the company received approval from the FDA ...
Moderna (MRNA) stock has been one of 2020’s star performers, up 695%, and judging by its real-world results, many would say justifiably so.The biggest question for investors, then, is whether ...